| Latest Commentary: | Volume VI, Number 126 |
|
House Sustains Bush’s SCHIP Veto -- The House failed, by just 13 votes, to over-ride the president’s veto of a bill expanding the State Children’s Health Insurance Program and spending $35 billion over the next 5 years. Although more than 40 Republicans voted against Mr. Bush, the 273 to 156 vote in favor failed to reach the constitutionally required 2/3 majority. The White House has won an ideological victory and has handed the Democrats a big stick with which to beat Republican candidates in 2008.
Former Prime Minister Benazir Bhutto Returns to Pakistan -- Yesterday, Pakistan’s former Prime Minister Benazir Bhutto arrived home after years of self-imposed exile. Tens of thousands lined the streets to cheer her arrival. “I have come here to serve the oppressed people of Pakistan,” she boldly announced. If she counts herself and General President Musharraf among the oppressed, then she has indeed come to serve them. Countrywide CEO Stock Sales Investigated -- Countywide Financial Corp. calls itself “America’s #1 Home Loan Lender,” and it got that way by getting involved in subprime mortgages. So naturally, it’s stock is down about 60% since February. Chief Executive Angelo R. Mozilo, who co-founded Countrywide in 1969, has been selling stock under a trading plan adopted in October 2006, just when the subprime crisis first hit the market’s attention. The SEC has launched an informal investigation. Malaria Vaccine Comes a Step Closer -- On Wednesday, researchers with the PATH Malaria Vaccine Initiative, funded by the Bill & Melinda Gates Foundation, announced that a new vaccine (Mosquirix or RTS,S/AS02) for malaria protected 65% of 214 Mozambican infants who had the full course of three injections. The results “show that we are making real progress toward a malaria vaccine," said Dr. Christian Loucq, director of the initiative. The next step is a Phase III trial about a year from now, involving 16,000 infants and young children in 7 African countries. If all goes well, the jabs would be on the market by 2012. © Copyright 2007 by The Kensington Review, Jeff Myhre, PhD, Editor. No part of this publication may be reproduced without written consent. Produced using Fedora Linux. |
|
